Advanced Or Metastatic Solid Tumours clinical trials

Explore recruiting advanced or metastatic solid tumours clinical trials.

Recruiting advanced or metastatic solid tumours studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Or Metastatic Solid Tumours trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an anti-PD-1 and anti-TIM-3 Bispecific Antibody, in Participants with Advanced or Metastatic Solid Tumors

Spain, Netherlands, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)

Spain, Poland

Phase I and Phase II (Integrated)- Other EU CTIS Study details

An Open-label, Phase I/II First in Human, Dose Escalation, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Participants With Locally Advanced or Metastatic Solid Tumours Who Have Progressed on or After Immune Checkpoint Inhibitor Therapies

Spain, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 1 Study to Assess Mass Balance, Pharmacokinetics, and Metabolism of [14C]Subasumstat in Patients With Advanced or Metastatic Solid Tumors

Hungary

Human Pharmacology (Phase I)- Other EU CTIS Study details

An Open-Label, Phase I/II First-in-Human, Dose Escalation, Dose Optimisation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 as Single Agent in Adult Participants with Locally Advanced or Metastatic Solid Tumours.

France, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Study of Orally Administered MOMA-313 in Participants with Advanced or Metastatic Solid Tumours

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Advanced Or Metastatic Solid Tumours trials by city

Advanced Or Metastatic Solid Tumours in Toronto Advanced Or Metastatic Solid Tumours in Vancouver Advanced Or Metastatic Solid Tumours in Montreal Advanced Or Metastatic Solid Tumours in Calgary Advanced Or Metastatic Solid Tumours in Edmonton Advanced Or Metastatic Solid Tumours in Ottawa Advanced Or Metastatic Solid Tumours in Winnipeg Advanced Or Metastatic Solid Tumours in Quebec City Advanced Or Metastatic Solid Tumours in Hamilton Advanced Or Metastatic Solid Tumours in Kitchener Advanced Or Metastatic Solid Tumours in London Advanced Or Metastatic Solid Tumours in Halifax Advanced Or Metastatic Solid Tumours in New York Advanced Or Metastatic Solid Tumours in Los Angeles Advanced Or Metastatic Solid Tumours in Chicago Advanced Or Metastatic Solid Tumours in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease